B. Riley analyst William Wood lowered the firm’s price target on Immunic (IMUX) to $5 from $6 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q1 report. Riley factored in the prospects of a likely near-term strategic financing to extend Immunic’s cash runway well beyond 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential
- Immunic’s Promising Clinical Data and Strategic Financial Position Justify Buy Rating
- Positive Phase 2 Trial Results for VidoCa in PMS Bolster Buy Rating for Immunic
- Biotech Alert: Searches spiking for these stocks today
- Promising Phase 2 Results for Vidofludimus Calcium in Progressive Multiple Sclerosis Highlight Potential for Neuroprotection and Disease Modification